<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Vet Res</journal-id><journal-id journal-id-type="iso-abbrev">BMC Vet. Res</journal-id><journal-title-group><journal-title>BMC Veterinary Research</journal-title></journal-title-group><issn pub-type="epub">1746-6148</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27829415</article-id><article-id pub-id-type="pmc">5103488</article-id><article-id pub-id-type="publisher-id">796</article-id><article-id pub-id-type="doi">10.1186/s12917-016-0796-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>In vitro susceptibility of four antimicrobials against <italic>Riemerella anatipestifer</italic> isolates: a comparison of minimum inhibitory concentrations and mutant prevention concentrations for ceftiofur, cefquinome, florfenicol, and tilmicosin</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Li</surname><given-names>Yafei</given-names></name><address><email>yafei.lee@163.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhang</surname><given-names>Yanan</given-names></name><address><email>247057465@qq.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Ding</surname><given-names>Huanzhong</given-names></name><address><email>hzding@scau.edu.cn</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Mei</surname><given-names>Xian</given-names></name><address><email>596171739@qq.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Wei</given-names></name><address><email>724265179@qq.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Zeng</surname><given-names>Jiaxiong</given-names></name><address><email>651385554@qq.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zeng</surname><given-names>Zhenling</given-names></name><address><phone>+86 2085281204</phone><email>zlzeng@scau.edu.cn</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1">Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, South China Agricultural University, Guangzhou, 510642 People&#x02019;s Republic of China </aff></contrib-group><pub-date pub-type="epub"><day>9</day><month>11</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>9</day><month>11</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>12</volume><elocation-id>250</elocation-id><history><date date-type="received"><day>5</day><month>12</month><year>2015</year></date><date date-type="accepted"><day>10</day><month>8</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Mutant prevention concentration (MPC) is an alternative pharmacodynamic parameter that has been used to measure antimicrobial activity and represents the propensities of antimicrobial agents to select resistant mutants. The concentration range between minimum inhibitory concentration (MIC) and MPC is defined as mutant selection window (MSW). The MPC and MSW parameters represent the ability of antimicrobial agents to inhibit the bacterial mutants selected. This study was conducted to determine the MIC and MPC values of four antimicrobials including ceftiofur, cefquinome, florfenicol and tilmicosin against 105 <italic>Riemerella anatipestifer</italic> isolates.</p></sec><sec><title>Results</title><p>The MIC<sub>50</sub>/MIC<sub>90</sub> values of clinical isolates tested in our study for ceftiofur, cefquinome, florfenicol and tilmicosin were 0.063/0.5&#x03001;0.031/0.5&#x03001;1/4&#x03001;1/4&#x000a0;&#x003bc;g/mL, respectively; MPC<sub>50</sub>/ MPC<sub>90</sub> values were 4/64&#x03001;8/64&#x03001;4/32&#x03001;16/256&#x000a0;&#x003bc;g/mL, respectively. These results provided information on the use of these compounds in treating the <italic>R. anatipestifer</italic> infection; however, additional studies are needed to demonstrate their therapeutic efficacy.</p></sec><sec><title>Conclusion</title><p>Based on the MSW theory, the hierarchy of these tested antimicrobial agents with respect to selecting resistant subpopulations was as follows: cefquinome&#x02009;&#x0003e;&#x02009;ceftiofur&#x02009;&#x0003e;&#x02009;tilmicosin&#x02009;&#x0003e;&#x02009;florfenicol. Cefquinome was the drug that presented the highest risk of selecting resistant mutant among the four antimicrobial agents.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd><italic>R. anatipestifer</italic></kwd><kwd>Minimum inhibitory concentration</kwd><kwd>Mutant prevention concentration</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>
<italic>Riemerella anatipestifer</italic> has been one of the most troublesome etiological agents and causes heavy loss in duck industry. It occurs worldwide, especially in Southeast Asia [<xref ref-type="bibr" rid="CR1">1</xref>]. The existence of <italic>R. anatipestifer</italic> infection symptoms observed is characterized by fibrinous pericarditis, perihepatitis, airsacculitis, caseous salpingitis, and meningitis. To date, at least twenty-one serotypes of <italic>R. anatipestifer</italic> have been identified and little cross-immunoprotection among serotypes was reported [<xref ref-type="bibr" rid="CR2">2</xref>]. People have been making great efforts to find new strategies to prevent or control <italic>R. anatipestifer</italic> infection, since much work has been done concentrating on the identification of factors associated with virulence [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>] and immunogenic characterization based on outer membrane protein A in recent years [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>]. Even so, chemotherapy is still a major approach in the treatment of <italic>R. anatipestifer</italic> infection because of the complex immunology situation currently. Due to the concern of high incidence of <italic>Riemerella anatipestifersis</italic> and increasingly severe drug resistance or reduction of susceptibility, obtaining new treatment information and promising results with antimicrobial agents seems necessary [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>].</p><p>Ceftiofur (&#x003b2;-lactam), cefquinome (&#x003b2;-lactam), florfenicol (phenicol), and tilmicosin (macrolide) belong to three families of antimicrobial agents and were developed for exclusive use in animals. They have exhibited remarkable antibacterial effects against diverse microorganisms since being introduced, although resistance to those drugs mentioned above has also been reported [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>]. The escalating resistance of <italic>R. anatipestifer</italic> field strains and concerns over animals as putative reservoirs for antimicrobial resistance genes force us to develop strategies to make full use of the current drugs [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR15">15</xref>].</p><p>Traditionally, the in vitro activity of antimicrobial susceptibility is assessed by minimum inhibitory concentration (MIC) or minimum bactericidal concentration (MBC). The mutant prevention concentration (MPC) concept is an alternative in vitro measurement of drug susceptibility against the infecting pathogen, representing the drug concentration that prevents a population of more than 10<sup>10</sup> colony forming unit (CFU)/mL bacteria from first mutation. Mutant selection window (MSW) is defined as the concentration range between MIC and MPC. The use of MPC and MSW is of aid in evaluating the capacity and potency of antimicrobial agents for the selection of resistant mutants [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p>Application of the MPC theory has been conducted in a variety of organisms associated with human and animals such as <italic>Escherichia coli</italic> [<xref ref-type="bibr" rid="CR17">17</xref>], <italic>Salmonella enterica</italic> [<xref ref-type="bibr" rid="CR18">18</xref>], <italic>Staphylococcus aureus</italic> [<xref ref-type="bibr" rid="CR19">19</xref>]<italic>, Pseudomonas aeruginosa</italic> [<xref ref-type="bibr" rid="CR20">20</xref>] and <italic>Mannheimia haemolytica</italic> [<xref ref-type="bibr" rid="CR21">21</xref>]. Essentially, the concept of MPC has been historically and primarily established for fluoroquinolones because of the resistance mechanisms for antimicrobial agents and is applicable to other classes under some restriction at present [<xref ref-type="bibr" rid="CR22">22</xref>]. So far, no published data of MPC have been available for <italic>R.anatipestifer</italic> yet. Therefore, the purpose of this study was to investigate the MPC of four antimicrobials against 105 <italic>R. anatipestifer</italic> isolates from China, providing advice on rational use of these antimicrobial agents, and further compare the potencies of these antimicrobials in selecting resistant <italic>R. anatipestifer</italic> mutants.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Bacterial strains</title><p>During the period of 2008 to 2014, we randomly collected <italic>R. anatipestifer</italic> isolates from the sick ducks or geese that exhibited typical symptoms of <italic>Riemerella anatipestifersis</italic> at the animal diagnostic departments of Guangdong Province, China. The clinical cases were provided by the farm owners who volunteered to participate in the study. A total of 105 <italic>R. anatipestifer</italic> clinical strains from ducks (<italic>n</italic>&#x02009;=&#x02009;98) and geese (<italic>n</italic>&#x02009;=&#x02009;7) were obtained and used in this study. The bacteria were identified by colony morphology and PCR method for partial sequence of outer membrane protein A as described previously [<xref ref-type="bibr" rid="CR23">23</xref>]. The Animal Experimentation Ethics Committee of South China Agricultural University approved all experimental procedures. In principal, MPC measurement should be performed against organisms sensitive to antimicrobial agents (by MIC testing). Because no critical susceptibility breakpoints were available for these four compounds against <italic>R. anatipestifer</italic>, the resistance breakpoints were tentatively interpreted according to the Clinical and Laboratory Standards Institute (CLSI) recommendation for <italic>E.coli</italic> or <italic>Pasteurella multocida</italic> [<xref ref-type="bibr" rid="CR24">24</xref>].</p></sec><sec id="Sec4"><title>Antimicrobial compounds</title><p>Antimicrobial agents exclusively approved for use in animals including ceftiofur, cefquinome, florfenicol, and tilmicosin were investigated in the present study. These compounds were commercially purchased from the manufactures in China. Stock solution of each antimicrobial was prepared in proper solvent according to the instructions of antimicrobial susceptibility testing for bacteria isolated from animals and stored at &#x02212;20&#x000a0;&#x000b0;C. <italic>Escherichia coli</italic> ATCC 25922 and <italic>Staphylococcus aureus</italic> ATCC 29213 were used as control strains.</p></sec><sec id="Sec5"><title>MIC measurements</title><p>Minimum inhibitory concentrations were determined by CLSI agar dilution methodology [<xref ref-type="bibr" rid="CR24">24</xref>]. All studies were carried out in triplicate. Briefly, each <italic>R. anatipestifer</italic> isolate in logarithmic growth period was diluted with 0.9&#x000a0;% saline to achieve a 0.5 McFarland standard suspension, equal to the inoculum of 5&#x02009;&#x000d7;&#x02009;10<sup>5</sup>&#x000a0;CFU/mL. About 5&#x000a0;&#x003bc;L suspensions were inoculated on Mueller-Hinton agar plates supplied with 5&#x000a0;% calf serum and containing antimicrobials (with a series of concentrations between 64 and 0.004&#x000a0;&#x003bc;g/mL). Inoculated plates were then incubated for 18&#x000a0;h at 37&#x000a0;&#x000b0;C in a constant temperature incubator. The MIC was recognized as the lowest antibiotic concentration showing no growth of colony morphology.</p></sec><sec id="Sec6"><title>MPC testing</title><p>The measurement of MPC was performed according to a method previously described with slight modification [<xref ref-type="bibr" rid="CR21">21</xref>]. Briefly, three or four colonies were inoculated into 3&#x000a0;mL <italic>R. anatipestifer</italic> broth (tryptic soy broth containing 0.5&#x000a0;% yeast and 5&#x000a0;% new calf serum) and cultured overnight. The next day, 100&#x000a0;&#x003bc;L <italic>R. anatipestifer</italic> suspensions were transferred to 100&#x000a0;mL of <italic>R. anatipestifer</italic> broth and shaken at the speed of 200&#x000a0;rpm under the temperature of 37&#x000a0;&#x000b0;C overnight. The collected cultures were concentrated by centrifugation at 4000&#x000a0;rpm for 20&#x000a0;min at 4&#x000a0;&#x000b0;C and then re-suspended in 5&#x000a0;mL of fresh <italic>R. anatipestifer</italic> broth to produce &#x02265;10<sup>10</sup>&#x000a0;CFU/mL suspensions. Aliquots of 100&#x000a0;&#x003bc;L containing &#x02265;10<sup>10</sup>&#x000a0;CFU/mL were applied to <italic>R. anatipestifer</italic> agar plates incorporating a series of antimicrobials with the concentrations ranging from 512 to 1&#x02009;&#x000d7;&#x02009;MIC. Each plate was prepared freshly, stored at 4&#x000a0;&#x000b0;C and used within 7&#x000a0;days. Inoculated plates were then incubated as described previously and observed for five days. MPC was taken as the lowest antimicrobial concentration that allowed no <italic>R. anatipestifer</italic> isolate growth. All MPC determinations were carried out in triplicate for each isolate. Results were identical and then used for data analysis. The ratio of MPC to MIC was also calculated.</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>MIC and MPC</title><p>A total of 98 <italic>R. anatipestifer</italic> isolates from ducks and 7 field strains from geese were tested against ceftiofur, cefquinome, florfenicol and tilmicosin. MICs and MPCs of antimicrobials assayed are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. MIC<sub>50/90</sub> and MPC<sub>50/90</sub> values are also shown. MPC values were higher than MICs because of exposure to higher density of bacterial inoculum. Following testing, MIC values of ceftiofur ranged from &#x02264;0.008 to 8&#x000a0;&#x003bc;g/mL, with MIC<sub>50</sub> and MIC<sub>90</sub> values of 0.063&#x000a0;&#x003bc;g/mL and 0.5&#x000a0;&#x003bc;g/mL respectively; cefquinome had the MIC values ranging between &#x02264;0.008 to 16&#x000a0;&#x003bc;g/mL, with MIC<sub>50</sub> of 0.031&#x000a0;&#x003bc;g/mL and MIC<sub>90</sub> of 0.5&#x000a0;&#x003bc;g/mL respectively; florfenicol had the MIC values ranging from 0.125 to 16&#x000a0;&#x003bc;g/mL, with MIC<sub>50</sub> of 1&#x000a0;&#x003bc;g/mL and MIC<sub>90</sub> of 4&#x000a0;&#x003bc;g/mL respectively; tilmicosin had the MIC values ranging from 0.031 to 64&#x000a0;&#x003bc;g/mL, with MIC<sub>50</sub> of 1&#x000a0;&#x003bc;g/mL and MIC<sub>90</sub> of 4&#x000a0;&#x003bc;g/mL respectively.<table-wrap id="Tab1"><label>Table 1</label><caption><p>MIC/MPC distribution for four compounds with clinical isolates of <italic>R. anatipestifer</italic> (<italic>n</italic>&#x02009;=&#x02009;105)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Drug</th><th colspan="16">Distribution of MIC and MPC values (&#x003bc;g/mL)</th></tr></thead><tbody><tr><td>Concentrations</td><td>&#x02264;0.008</td><td>0.016</td><td>0.031</td><td>0.063</td><td>0.125</td><td>0.25</td><td>0.5</td><td>1</td><td>2</td><td>4</td><td>8</td><td>16</td><td>32</td><td>64</td><td>&#x02265;128</td><td>MIC<sub>50</sub>/MIC<sub>90</sub>
</td></tr><tr><td>MIC distribution</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x02003;Ceftiofur</td><td>3</td><td>8</td><td>25</td><td>22</td><td>16</td><td>13</td><td>10</td><td>3</td><td>1</td><td>2</td><td>2</td><td/><td/><td/><td/><td>0.063/0.5</td></tr><tr><td>&#x02003;Cefquinome</td><td>28</td><td>22</td><td>15</td><td>6</td><td>12</td><td>9</td><td>5</td><td>3</td><td>3</td><td/><td>1</td><td>1</td><td/><td/><td/><td>0.031/0.5</td></tr><tr><td>&#x02003;Florfenicol</td><td/><td/><td/><td/><td>1</td><td>1</td><td>28</td><td>25</td><td>37</td><td>6</td><td>6</td><td>1</td><td/><td/><td/><td>1/4</td></tr><tr><td>&#x02003;Tilmicosin</td><td/><td/><td>1</td><td>14</td><td>7</td><td>9</td><td>7</td><td>20</td><td>24</td><td>13</td><td>5</td><td>2</td><td>2</td><td>1</td><td/><td>1/4</td></tr><tr><td>MPC distribution</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td>MPC<sub>50</sub>/MPC<sub>90</sub>
</td></tr><tr><td>&#x02003;Ceftiofur<sup>a</sup>
</td><td/><td/><td/><td/><td>1</td><td>2</td><td>4</td><td>16</td><td>19</td><td>11</td><td>17</td><td>2</td><td>17</td><td>12</td><td>2</td><td>4/64</td></tr><tr><td>&#x02003;Cefquinome<sup>b</sup>
</td><td/><td/><td/><td/><td/><td>2</td><td>1</td><td>4</td><td>14</td><td>17</td><td>24</td><td>14</td><td>10</td><td>9</td><td>8</td><td>8/64</td></tr><tr><td>&#x02003;Florfenicol<sup>c</sup>
</td><td/><td/><td/><td/><td/><td/><td/><td>11</td><td>21</td><td>21</td><td>22</td><td>9</td><td>10</td><td>3</td><td>1</td><td>4/32</td></tr><tr><td>&#x02003;Tilmicosin<sup>d</sup>
</td><td/><td/><td/><td/><td/><td>2</td><td>1</td><td>7</td><td>4</td><td>10</td><td>22</td><td>10</td><td>10</td><td>5</td><td>31</td><td>16/256</td></tr></tbody></table><table-wrap-foot><p>MIC<sub>50</sub> and MIC<sub>90</sub> -the drug concentration at which 50&#x000a0;% or 90&#x000a0;% of the isolates are inhibited, respectively</p><p>MPC<sub>50</sub> and MPC<sub>90</sub>-the drug concentration restricting the growth of mutant subpopulation for 50&#x000a0;% or 90&#x000a0;% respectively of the isolates tested</p><p>
<sup>a</sup> Testing against 103 isolates</p><p>
<sup>b</sup> Testing against 103 isolates</p><p>
<sup>c</sup> Testing against 98 isolates</p><p>
<sup>d</sup> Testing against 102 isolates</p></table-wrap-foot></table-wrap>
</p><p>The corresponding MPC values of the four antimicrobial agents assayed against 105 <italic>R. anatipestifer</italic> isolates are also listed in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Following testing of ceftiofur, MPC values ranged from 0.125 to &#x02265;128&#x000a0;&#x003bc;g/mL, with MPC<sub>50</sub> and MPC<sub>90</sub> values of 4 and 64&#x000a0;&#x003bc;g/mL respectively; for cefquinome from 0.25 to &#x02265;128&#x000a0;&#x003bc;g/mL and 8 and 64&#x000a0;&#x003bc;g/mL respectively; for florfenicol from 1 to &#x02265;128&#x000a0;&#x003bc;g/mL and 4 and 32&#x000a0;&#x003bc;g/mL respectively; for tilmicosin from 0.25 to &#x02265;128&#x000a0;&#x003bc;g/mL and 16 and 256&#x000a0;&#x003bc;g/mL respectively.</p><p>Based on these MIC and MPC values, dosing to achieve the MIC or MPC values (where possible) may serve to inhibit susceptible bacterium or reduce the selection of resistant mutants. The hierarchy of potency for these tested agents based on MIC<sub>90</sub> values was: ceftiofur&#x02009;=&#x02009;cefquinome&#x02009;&#x0003e;&#x02009;florfenicol&#x02009;=&#x02009;tilmicosin. The potency of antimicrobial agents tested based on MPC<sub>90</sub> values followed the rank order: florfenicol&#x02009;&#x0003e;&#x02009;ceftiofur&#x02009;=&#x02009;cefquinome&#x02009;&#x0003e;&#x02009;tilmicosin.</p></sec><sec id="Sec9"><title>Mutant selection index calculations</title><p>The ratio of MPC to MIC was defined as selection index (SI) [<xref ref-type="bibr" rid="CR25">25</xref>]. The lower SI is, the better ability of antimicrobials to restrict the resistant mutant subpopulations. Since working with a large population of <italic>R. anatipestifer</italic> isolates is cumbersome, we calculated the mutant selection index (ratio of MPC to MIC) for each isolate so that the capacity of selecting mutant enrichment for each antimicrobial agent could be easily compared. The value distribution for each antimicrobial agent was shown in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. In our investigation, MPC/MIC ratios were slightly lower for florfenicol and higher for cefquinome. The SI data indicated a better ability of florfenicol to prevent non-susceptible mutant subpopulations and a strong selective pressure of cefquinome to enrich <italic>R. anatipestifer</italic> mutants.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Distribution of different ratios of MPC to MIC for clinical isolates of <italic>R. anatipestifer</italic>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Drug</th><th colspan="11">No. of isolates having different ratios of MPC to MIC</th></tr><tr><th>1</th><th>2</th><th>4</th><th>8</th><th>16</th><th>32</th><th>64</th><th>128</th><th>256</th><th>512</th><th>&#x0003e;512</th></tr></thead><tbody><tr><td>Ceftiofur<sup>a</sup>
</td><td>1</td><td>3</td><td>1</td><td>8</td><td>6</td><td>22</td><td>25</td><td>14</td><td>8</td><td>6</td><td>9</td></tr><tr><td>Cefquinome<sup>b</sup>
</td><td>0</td><td>0</td><td>0</td><td>3</td><td>5</td><td>9</td><td>5</td><td>11</td><td>25</td><td>22</td><td>23</td></tr><tr><td>Florfenicol <sup>c</sup>
</td><td>6</td><td>25</td><td>30</td><td>18</td><td>12</td><td>5</td><td>2</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Tilmicosin <sup>d</sup>
</td><td>1</td><td>5</td><td>15</td><td>20</td><td>8</td><td>17</td><td>14</td><td>10</td><td>5</td><td>3</td><td>4</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup> Testing against 103 isolates</p><p>
<sup>b</sup> Testing against 103 isolates</p><p>
<sup>c</sup> Testing against 98 isolates</p><p>
<sup>d</sup> Testing against 102 isolates</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec10"><title>Pharmacokinetics/Pharmacodynamics (PK/PD) calculations</title><p>We also selected MIC<sub>90</sub> and MPC<sub>90</sub> as the boundaries of the mutant selective window [<xref ref-type="bibr" rid="CR26">26</xref>]. Plasma pharmacokinetic data in ducks were available for cefquinome and florfenicol [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. In conjunction with pharmacokinetic parameters of each compound in ducks, the various PK/PD indices, including ratio of maximum plasma concentration to MIC<sub>90</sub> (C<sub>max</sub>/MIC<sub>90</sub>) or MPC<sub>90</sub> (C<sub>max</sub>/MPC<sub>90</sub>), ratio of area under the concentration-time curve to MIC<sub>90</sub> (AUC/MIC<sub>90</sub>) or MPC<sub>90</sub> (AUC/MPC<sub>90</sub>), time above MIC<sub>90 </sub>or MPC<sub>90</sub> of the dosage interval ( %<italic>T</italic>&#x0003e;MIC<sub>90 </sub>or %<italic>T</italic>&#x0003e;MPC<sub>90</sub>), and time inside the mutant selection window of the dosage interval (%<italic>T</italic>
<sub>MSW</sub>), are shown in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. %<italic>T</italic>&#x02009;&#x0003e;&#x02009;MIC serves as an important parameter for cephalosporins and its value of cefquinome against <italic>R. anatipestifer</italic> isolates was approximately 31.67&#x000a0;% by integrating the pharmacokinetic values obtained from a intramuscular injection of a dose of 5&#x000a0;mg/kg body weight [<xref ref-type="bibr" rid="CR27">27</xref>]. No concentration was observed to exceed the MPC<sub>90</sub>. According to the pharmacokinetic data attained with a single dose of 30&#x000a0;mg/kg body weight florfenicol intramuscularly [<xref ref-type="bibr" rid="CR28">28</xref>], the values determined for C<sub>max</sub>/MIC<sub>90</sub>, C<sub>max</sub>/MPC<sub>90</sub>, AUC<sub>24</sub>/MIC<sub>90</sub>, AUC<sub>24</sub>/MPC<sub>90</sub> were 1.62, 0.10, 18.21&#x000a0;h and 1.14&#x000a0;h for florfenicol, respectively. All the concentrations of florfenicol in plasma were lower than MPC<sub>90</sub> and %<italic>T</italic>
<sub>MSW</sub> was calculated to be approximately 21.67&#x000a0;%.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Pharmacokinetics and pharmacodynamics variables in plasma for two antimicrobial agents against <italic>R. anatipestifer</italic> isolates</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Antimicrobial</th><th>Dosage regimen (mg/kg)</th><th>C<sub>max</sub> (&#x003bc;g/mL)</th><th>AUC<sub>24h</sub> (&#x003bc;g&#x000a0;h/mL)</th><th>C<sub>max</sub>/MIC<sub>90</sub>
</th><th>C<sub>max</sub>/MPC<sub>90</sub>
</th><th>AUC<sub>24</sub>/MIC<sub>90</sub> (h)</th><th>AUC<sub>24</sub>/MPC<sub>90</sub> (h)</th><th>
<italic>T</italic>&#x02009;&#x0003e;&#x02009;MIC<sub>90</sub> (h)</th><th>
<italic>T</italic>&#x02009;&#x0003e;&#x02009;MPC<sub>90</sub> (h)</th><th>%<italic>T</italic>
<sub>MSW</sub>
</th></tr></thead><tbody><tr><td>Cefquinome<sup>a</sup>
</td><td>5, IM</td><td char="." align="char">9.38</td><td char="." align="char">23.78</td><td char="." align="char">18.76</td><td char="." align="char">0.15</td><td char="." align="char">47.56</td><td char="." align="char">0.37</td><td>~7.6</td><td>0</td><td char="." align="char">31.67</td></tr><tr><td>Florfenicol<sup>b</sup>
</td><td>30, IM</td><td char="." align="char">3.24</td><td char="." align="char">36.42</td><td char="." align="char">1.62</td><td char="." align="char">0.10</td><td char="." align="char">18.21</td><td char="." align="char">1.14</td><td>~5.2</td><td>0</td><td char="." align="char">21.67</td></tr></tbody></table><table-wrap-foot><p>
<italic>C</italic>
<sub><italic>max</italic></sub> serum maximum concentration, <italic>AUC</italic>
<sub><italic>24h</italic></sub> area under curve over a 24&#x000a0;h time period, <italic>MIC</italic> minimum inhibitory concentration, <italic>MPC</italic> mutant prevention concentration, <italic>T</italic>
<sub><italic>MSW</italic></sub> time inside the mutant selection window, <italic>IM</italic> intramuscularly</p><p>
<sup>a</sup> based on data as published by Yuan et al</p><p>
<sup>b</sup> based on data as published by EL-Banna</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec11"><title>Discussion</title><p>
<italic>Riemerella anatipestifer</italic> has been a problematic pathogen of commercial importance for several years and it is hard to give the correct treatment measures. One possible reason is poor cross immune protection among various serotypes; another important reason may be due to the similarity of clinical symptom between <italic>R. anatipestifer</italic> infection and <italic>E. coli</italic> infection. In recent years, <italic>R. anatipestifer</italic> strains with reduced susceptibility to antimicrobials have emerged as reported in other&#x02019;s study and our previous investigation [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR23">23</xref>] because of the use of antimicrobials in animals, which reflects the necessity of searching for new compounds or strategies to treat <italic>Riemerella anatipestifersis</italic> [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]<italic>.</italic> Maintaining the utility of antimicrobials in treating <italic>Riemerella anatipestifersis</italic> seems to be a major challenge. As proposed by other researchers, one of the strategies to tackle the resistance problem is to reduce or prevent the emergence of resistant mutants [<xref ref-type="bibr" rid="CR19">19</xref>]. In human medicine, MPC values and MPC/MIC ratios have been determined and studied extensively in a large number of antimicrobial agents, involving many kinds of organisms [<xref ref-type="bibr" rid="CR29">29</xref>&#x02013;<xref ref-type="bibr" rid="CR32">32</xref>]. In the current study, we first report the MPC values of four antimicrobials that were exclusively developed for animals against 105 <italic>R. anatipestifer</italic> field strains mainly isolated from South of China.</p><p>We selected several antimicrobial agents that were approved exclusively and most commonly used in animals, and also represented a wide range of antimicrobial agents. To our surprise, up to 70&#x000a0;% strains had high MIC values of enrofloxacin (&#x02265;2&#x000a0;&#x003bc;g/mL) and apramycin (&#x02265;64&#x000a0;&#x003bc;g/mL) (data not shown). Based on the MIC data of the six compounds, four antimicrobial agents tested in our study appeared to have excellent in vitro activities against <italic>R. anatipestifer</italic> strains, although they have different chemical structures and action mechanisms. Previously, Blondeau et al. [<xref ref-type="bibr" rid="CR21">21</xref>] compared the MIC and MPC values of five antimicrobial agents against bovine clinical isolates of <italic>Mannheimia haemolytica</italic>. The rank order of potency that antimicrobials selected resistant mutants differed by using MIC and MPC data. Such is the case for <italic>R. anatipestifer</italic> isolates.</p><p>The concentration zone between MIC and MPC was recognized as MSW. Concentrations of antimicrobials within MSW exerted a selective pressure for accumulation of resistant strains. Ratio of MPC to MIC represented the ability of antimicrobial agents to block the resistant mutant subpopulation. MPC, MSW and MPC/MIC ratio served as a guide for the potency of antimicrobials in restricting resistant mutant selection. Based on these, a large number of references tried to address the issue of relationship between antimicrobials and bacteria. Hansen et al. [<xref ref-type="bibr" rid="CR20">20</xref>] thought ciprofloxacin was more active than levofloxacin in selecting resistant <italic>Pseudomonas aeruginosa</italic> amplification. By determining the MPC of three quinolones against 100 clinical Streptococcus <italic>pneumococci</italic>, moxifloxacin seemed to exhibit more excellent antimutant ability than levofloxacin and gemifloxin [<xref ref-type="bibr" rid="CR33">33</xref>]. Wang et al. [<xref ref-type="bibr" rid="CR34">34</xref>] tested the MPC of three quinolones against <italic>Campylobacter jejuni</italic> isolated from chicken and assumed that enrofloxacin had the lowest MPC among the three tested quinolones, thus enrofloxacin represented a low selective pressure for selection of resistant subpopulations. Briales et al. [<xref ref-type="bibr" rid="CR35">35</xref>] provided the MPC values of fluoroquinolone against <italic>E. coli</italic> isolates carrying different plasmid-mediated resistant genes <italic>qnr</italic> and harboring isogenic <italic>gyrA</italic> and <italic>parC</italic> substitutions, considering that <italic>qnr</italic> genes played a vital role in selecting one-step resistant mutants. From our results, florfenicol appeared to be a compound with excellent in vitro activity against these <italic>R. anatipestifer</italic> strains collected from South China, although some mechanism of <italic>R. anatipestifer</italic> isolates resistant to florfenicol has been described in other districts [<xref ref-type="bibr" rid="CR36">36</xref>].</p><p>The ratio of MPC/MIC was slightly higher for ceftiofur and cefquinome among the four antimicrobials tested (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Even two cephalosporins developed for animals are only used in veterinary medicine, and they are classified as critically important antimicrobials by the WHO [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>], their use to treat great numbers of animals in duck industry is to be strongly discouraged because of prudent use guidelines. Similar conclusion was also obtained for the therapy of <italic>R. anatipestifer</italic> infection based on the theory of MPC and MSW. In addition, both ceftiofur and cefquinome cannot be administered orally because of poor absorption; unless used prophylactically, which would be in strong contradiction to prudent use guidelines, therefore the usefulness of ceftiofur and cefquinome may probably be reduced in duck production to a bare minimum. Although ceftiofur has successfully cured the <italic>R. anatipestifer</italic> infection in a previous report [<xref ref-type="bibr" rid="CR39">39</xref>], it should not be the first choice considering the wider MSW and severe drug resistance situation. The MSW of cefquinome was wider than that of ceftiofur. In other words, cefquinome has weaker ability of preventing the selection of <italic>R. anatipestifer</italic> mutants than ceftiofur. Comparing MSWs and MPC/MIC ratios of the four antimicrobials, cefquinome seems to be the drug that most easily selects resistant mutants.</p><p>MIC or MPC-based therapeutic protocols and PK/PD indices for suppressing the enrichment of resistant bacterial subpopulations have been proposed and studied in various in vivo or in vitro models extensively [<xref ref-type="bibr" rid="CR40">40</xref>&#x02013;<xref ref-type="bibr" rid="CR43">43</xref>]. PK/PD parameters such as AUC/MIC, C<sub>max</sub>/MIC and T&#x02009;&#x0003e;&#x02009;MIC relate closely with the effect of antimicrobials. In our laboratory, pharmacodynamics on the basis of MIC values for cefquinome have been well studied in mice, yellow cattle, pigs and dogs against a series of microorganisms in recent years, involving <italic>E. coli</italic>, <italic>S. aureus</italic>, <italic>P. multocida</italic>, <italic>Klebsiella pneumoniae</italic> as well as <italic>Haemophilus parasuis</italic> [<xref ref-type="bibr" rid="CR44">44</xref>&#x02013;<xref ref-type="bibr" rid="CR50">50</xref>]. These publications clearly described the relationship between the dosing schedules and the antimicrobial effectiveness. Also, the ability of cefquinome to restrict the selection of <italic>E. coli</italic> mutants was predicted in an in vivo model. The results demonstrated that %<italic>T</italic>&#x02009;&#x0003e;&#x02009;MPC of &#x0003e;50&#x000a0;% was favorable to block the resistant mutants [<xref ref-type="bibr" rid="CR43">43</xref>]. By integrating our results with the published pharmacokinetic data of antimicrobials in ducks, serum drug concentrations of cefquinome and florfenicol may fall within the MSW and the high MPC values could hardly be attained albeit these two drugs had excellent MIC values. As cephalosporin exhibited time-dependent property, we applied this approach in our study and the predicted <italic>T</italic>&#x02009;&#x0003e;&#x02009;MIC was approximately 7.6&#x000a0;h (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>), which was lower than that obtained previously using <italic>P. multocida</italic> in yellow cattle [<xref ref-type="bibr" rid="CR46">46</xref>], but slightly higher than that calculated using canine <italic>E. coli</italic> [<xref ref-type="bibr" rid="CR50">50</xref>]. In vivo antimicrobial efficacy of cefquinome against <italic>R. anatipestifer</italic> should be further addressed. Little is known on the PK/PD relationship of florfenicol against <italic>R. anatipestifer</italic>. Until now, no killing studies of ceftiofur and tilmicosin based on MIC or MPC parameters of <italic>R. anatipestifer</italic> have been conducted in ducks. So more work based on the MSW theory should be performed for the use of antimicrobial agents in ducks.</p></sec><sec id="Sec12"><title>Conclusions</title><p>This is the first study that described the MIC and MPC values of four antimicrobial agents developed exclusively for animals against <italic>R. anatipestifer</italic> isolates. Our study may shed light on the future antimicrobial therapies for treatment of <italic>R. anatipestifer</italic> infection. Further in vivo or in vitro studies are required to confirm the efficacy based on the MIC or MPC values. The mutant selection window hypothesis suggests that cefquinome is least likely to prevent the emergence of <italic>R. anatipestifer</italic> mutants among the four antimicrobials.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>CFU</term><def><p>Colony Forming Unit</p></def></def-item><def-item><term>CLSI</term><def><p>Clinical and Laboratory Standards Institute</p></def></def-item><def-item><term>MBC</term><def><p>Minimum Bactericidal Concentration</p></def></def-item><def-item><term>MIC</term><def><p>Minimum Inhibitory Concentration</p></def></def-item><def-item><term>MPC</term><def><p>Mutant Prevention Concentration</p></def></def-item><def-item><term>MSW</term><def><p>Mutant Selection Window</p></def></def-item><def-item><term>PD</term><def><p>Pharmacodynamics</p></def></def-item><def-item><term>PK</term><def><p>Pharmacokinetics</p></def></def-item><def-item><term>SI</term><def><p>Selection Index</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>We thank Dr. Rong Xiang for the technical assistance of identifying isolates.</p><sec id="FPar1"><title>Funding</title><p>This work was financially supported by the Program for Changjiang Scholars and Innovative Research Team in University of Ministry of Education of China (Grant No.IRT13063) and National Natural Science Foundation of China (Grant No.31072169).</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p>All the data supporting our findings is contained within the manuscript.</p></sec><sec id="FPar3"><title>Authors&#x02019; contributions</title><p>ZLZ conceived and designed the experiments. YFL, YNZ, XM, WL and JXZ performed all the experiments. YFL wrote the first draft of the manuscript. HZD revised the manuscript. All authors read and approved the final manuscript.</p></sec><sec id="FPar4"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar5"><title>Consent for publication</title><p>Not applicable.</p></sec><sec id="FPar6"><title>Ethics approval and consent to participate</title><p>The Ethics Committee of South China Agricultural University approved the study.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crasta</surname><given-names>KC</given-names></name><name><surname>Chua</surname><given-names>K-L</given-names></name><name><surname>Subramaniam</surname><given-names>S</given-names></name><name><surname>Frey</surname><given-names>J</given-names></name><name><surname>Loh</surname><given-names>H</given-names></name><name><surname>Tan</surname><given-names>H-M</given-names></name></person-group><article-title>Identification and characterization of CAMP cohemolysin as a potential virulence factor of <italic>Riemerella anatipestifer</italic></article-title><source>J Bacteriol</source><year>2002</year><volume>184</volume><issue>7</issue><fpage>1932</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1128/JB.184.7.1932-1939.2002</pub-id><pub-id pub-id-type="pmid">11889100</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Pathanasophon P, Sawada T, Pramoolsinsap T, Tanticharoenyos T. Immunogenicity of <italic>Riemerella anatipestifer</italic> broth culture bacterin and cell-free culture filtrate in ducks. Avian Pathol. 1996;25(4):705&#x02013;19.</mixed-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weng</surname><given-names>SC</given-names></name><name><surname>Lin</surname><given-names>WH</given-names></name><name><surname>Chang</surname><given-names>YF</given-names></name><name><surname>Chang</surname><given-names>CF</given-names></name></person-group><article-title>Identification of a virulence-associated protein homolog gene and IS<italic>Ra1</italic> in a plasmid of <italic>Riemerella anatipestifer</italic></article-title><source>FEMS Microbiol Lett</source><year>1999</year><volume>179</volume><issue>1</issue><fpage>11</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6968.1999.tb08701.x</pub-id><pub-id pub-id-type="pmid">10481080</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Q</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Ding</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name></person-group><article-title>OmpA is a virulence factor of <italic>Riemerella anatipestifer</italic></article-title><source>Vet Microbiol</source><year>2011</year><volume>150</volume><issue>3</issue><fpage>278</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2011.01.022</pub-id><pub-id pub-id-type="pmid">21349662</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>B</given-names></name><name><surname>Kwang</surname><given-names>J</given-names></name><name><surname>Loh</surname><given-names>H</given-names></name><name><surname>Frey</surname><given-names>J</given-names></name><name><surname>Tan</surname><given-names>H-M</given-names></name><name><surname>Chua</surname><given-names>K-L</given-names></name></person-group><article-title>Development of an ELISA using a recombinant 41&#x000a0;kDa partial protein (P45N&#x02032;) for the detection of <italic>Riemerella anatipestifer</italic> infections in ducks</article-title><source>Vet Microbiol</source><year>2002</year><volume>88</volume><issue>4</issue><fpage>339</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/S0378-1135(02)00123-2</pub-id><pub-id pub-id-type="pmid">12220809</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Q</given-names></name><name><surname>Ding</surname><given-names>C</given-names></name><name><surname>Tu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Duan</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Immunoproteomics analysis of whole cell bacterial proteins of <italic>Riemerella anatipestifer</italic></article-title><source>Vet Microbiol</source><year>2012</year><volume>157</volume><issue>3</issue><fpage>428</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2012.01.009</pub-id><pub-id pub-id-type="pmid">22317978</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>C-Y</given-names></name><name><surname>Liu</surname><given-names>C-H</given-names></name><name><surname>Liou</surname><given-names>J-J</given-names></name><name><surname>Lee</surname><given-names>J-W</given-names></name><name><surname>Cheng</surname><given-names>L-T</given-names></name></person-group><article-title>Development of a subunit vaccine containing recombinant <italic>Riemerella anatipestifer</italic> outer membrane protein A and CpG ODN adjuvant</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><issue>1</issue><fpage>92</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.11.010</pub-id><pub-id pub-id-type="pmid">25448104</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>CY</given-names></name><name><surname>Cheng</surname><given-names>AC</given-names></name><name><surname>Wang</surname><given-names>MS</given-names></name><name><surname>Zhu</surname><given-names>DK</given-names></name><name><surname>Luo</surname><given-names>QH</given-names></name><name><surname>De Zhong</surname><given-names>C</given-names></name><etal/></person-group><article-title>Antibiotic susceptibility of <italic>Riemerella anatipestifer</italic> field isolates</article-title><source>Avian Dis</source><year>2009</year><volume>53</volume><issue>4</issue><fpage>601</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1637/8552-120408-ResNote.1</pub-id><pub-id pub-id-type="pmid">20095163</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>F</given-names></name><name><surname>Lin</surname><given-names>G</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Gong</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><etal/></person-group><article-title>Discovery and characterization of gene cassettes-containing integrons in clinical strains of <italic>Riemerella anatipestifer</italic></article-title><source>Vet Microbiol</source><year>2012</year><volume>156</volume><issue>3</issue><fpage>434</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2011.11.002</pub-id><pub-id pub-id-type="pmid">22112855</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>F-F</given-names></name><name><surname>Sun</surname><given-names>Y-N</given-names></name><name><surname>Li</surname><given-names>J-X</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>M-J</given-names></name><name><surname>Su</surname><given-names>J</given-names></name><etal/></person-group><article-title>Detection of aminoglycoside resistance genes in <italic>Riemerella anatipestifer</italic> isolated from ducks</article-title><source>Vet Microbiol</source><year>2012</year><volume>158</volume><issue>3</issue><fpage>451</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2012.02.027</pub-id><pub-id pub-id-type="pmid">22445728</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Zeng</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>High prevalence of plasmid-mediated quinolone resistance determinants <italic>qnr</italic>, <italic>aac (6&#x02032;)-Ib-cr</italic>, and <italic>qepA</italic> among ceftiofur-resistant <italic>Enterobacteriaceae</italic> isolates from companion and food-producing animals</article-title><source>Antimicrob Agents Chemother</source><year>2009</year><volume>53</volume><issue>2</issue><fpage>519</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1128/AAC.00886-08</pub-id><pub-id pub-id-type="pmid">18936192</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corti</surname><given-names>S</given-names></name><name><surname>Sicher</surname><given-names>D</given-names></name><name><surname>Regli</surname><given-names>W</given-names></name><name><surname>Stephan</surname><given-names>R</given-names></name></person-group><article-title>Current data on antibiotic resistance of the most important bovine mastitis pathogens in Switzerland</article-title><source>Schweiz Arch Tierheilkd</source><year>2003</year><volume>145</volume><issue>12</issue><fpage>571</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1024/0036-7281.145.12.571</pub-id><pub-id pub-id-type="pmid">14725183</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>DG</given-names></name><name><surname>Hudson</surname><given-names>C</given-names></name><name><surname>Maurer</surname><given-names>JJ</given-names></name><name><surname>Ayers</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Characterization of chloramphenicol and florfenicol resistance in <italic>Escherichia coli</italic> associated with bovine diarrhea</article-title><source>J Clin Microbiol</source><year>2000</year><volume>38</volume><issue>12</issue><fpage>4593</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11101601</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Ioana V, Herman V, Pascu C, Bogdan F, Csuka E, Biksi I. Antimicrobial susceptibility of some <italic>Actinobacillus pleuropneumoniae </italic>strains. Bulletin of University of Agricultural Sciences and Veterinary Medicine Cluj-Napoca. Vet Med. 2011;2(68):300-2.</mixed-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bates</surname><given-names>J</given-names></name><name><surname>Jordens</surname><given-names>JZ</given-names></name><name><surname>Griffiths</surname><given-names>DT</given-names></name></person-group><article-title>Farm animals as a putative reservoir for vancomycin-resistant enterococcal infection in man</article-title><source>J Antimicrob Chemother</source><year>1994</year><volume>34</volume><issue>4</issue><fpage>507</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1093/jac/34.4.507</pub-id><pub-id pub-id-type="pmid">7868403</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Domagala</surname><given-names>J</given-names></name><name><surname>Drlica</surname><given-names>K</given-names></name></person-group><article-title>Effect of fluoroquinolone concentration on selection of resistant mutants of <italic>Mycobacterium bovis</italic> BCG and <italic>Staphylococcus aureus</italic></article-title><source>Antimicrob Agents Chemother</source><year>1999</year><volume>43</volume><issue>7</issue><fpage>1756</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10390236</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linde</surname><given-names>H-J</given-names></name><name><surname>Lehn</surname><given-names>N</given-names></name></person-group><article-title>Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for <italic>Escherichia coli</italic> under different growth conditions</article-title><source>Antimicrob Agents Chemother</source><year>2004</year><volume>53</volume><issue>2</issue><fpage>252</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1093/jac/dkh036</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kehrenberg</surname><given-names>C</given-names></name><name><surname>de Jong</surname><given-names>A</given-names></name><name><surname>Friederichs</surname><given-names>S</given-names></name><name><surname>Cloeckaert</surname><given-names>A</given-names></name><name><surname>Schwarz</surname><given-names>S</given-names></name></person-group><article-title>Molecular mechanisms of decreased susceptibility to fluoroquinolones in avian <italic>Salmonella serovars</italic> and their mutants selected during the determination of mutant prevention concentrations</article-title><source>J Antimicrob Chemother</source><year>2007</year><volume>59</volume><issue>5</issue><fpage>886</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1093/jac/dkm072</pub-id><pub-id pub-id-type="pmid">17369276</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metzler</surname><given-names>K</given-names></name><name><surname>Hansen</surname><given-names>G</given-names></name><name><surname>Hedlin</surname><given-names>P</given-names></name><name><surname>Harding</surname><given-names>E</given-names></name><name><surname>Drlica</surname><given-names>K</given-names></name><name><surname>Blondeau</surname><given-names>J</given-names></name></person-group><article-title>Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and-resistant <italic>Staphylococcus aureus</italic></article-title><source>Int J Antimicrob Agents</source><year>2004</year><volume>24</volume><issue>2</issue><fpage>161</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2004.02.021</pub-id><pub-id pub-id-type="pmid">15288315</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>GT</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Drlica</surname><given-names>K</given-names></name><name><surname>Blondeau</surname><given-names>JM</given-names></name></person-group><article-title>Mutant prevention concentration for ciprofloxacin and levofloxacin with <italic>Pseudomonas aeruginosa</italic></article-title><source>Int J Antimicrob Agents</source><year>2006</year><volume>27</volume><issue>2</issue><fpage>120</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2005.10.005</pub-id><pub-id pub-id-type="pmid">16426820</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blondeau</surname><given-names>J</given-names></name><name><surname>Borsos</surname><given-names>S</given-names></name><name><surname>Blondeau</surname><given-names>L</given-names></name><name><surname>Blondeau</surname><given-names>B</given-names></name><name><surname>Hesje</surname><given-names>C</given-names></name></person-group><article-title>Comparative minimum inhibitory and mutant prevention drug concentrations of enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin against bovine clinical isolates of <italic>Mannheimia haemolytica</italic></article-title><source>Vet Microbiol</source><year>2012</year><volume>160</volume><issue>1</issue><fpage>85</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2012.05.006</pub-id><pub-id pub-id-type="pmid">22677482</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>HJ</given-names></name><name><surname>Nichol</surname><given-names>KA</given-names></name><name><surname>Hoban</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Stretching the mutant prevention concentration (MPC) beyond its limits</article-title><source>J Antimicrob Chemother</source><year>2003</year><volume>51</volume><issue>6</issue><fpage>1323</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1093/jac/dkg255</pub-id><pub-id pub-id-type="pmid">12716780</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>J-H</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Lin</surname><given-names>D-C</given-names></name><name><surname>Li</surname><given-names>G-H</given-names></name><name><surname>Chen</surname><given-names>Z-L</given-names></name><etal/></person-group><article-title>Molecular characterization of the antimicrobial resistance of <italic>Riemerella anatipestifer</italic> isolated from ducks</article-title><source>Vet Microbiol</source><year>2012</year><volume>158</volume><issue>3</issue><fpage>376</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2012.03.005</pub-id><pub-id pub-id-type="pmid">22464155</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Clinical Laboratory Standards Institute (CLSI)</collab></person-group><source>Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals; Approved Standard-Fourth Edition. CLSI document VET01-A4 and VET01-S2</source><year>2013</year><publisher-loc>Wayne</publisher-loc><publisher-name>CLSI</publisher-name></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Drlica</surname><given-names>K</given-names></name></person-group><article-title>Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window</article-title><source>J Infect Dis</source><year>2002</year><volume>185</volume><issue>4</issue><fpage>561</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1086/338571</pub-id><pub-id pub-id-type="pmid">11865411</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Drlica</surname><given-names>K</given-names></name></person-group><article-title>Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies</article-title><source>Clin Infect Dis</source><year>2001</year><volume>33</volume><fpage>S147</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1086/321841</pub-id><pub-id pub-id-type="pmid">11524712</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><etal/></person-group><article-title>Pharmacokinetics and bioavailability of cefquinome in healthy ducks</article-title><source>Am J Vet Res</source><year>2011</year><volume>72</volume><issue>1</issue><fpage>122</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.2460/ajvr.72.1.122</pub-id><pub-id pub-id-type="pmid">21194344</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Banna</surname><given-names>H</given-names></name></person-group><article-title>Pharmacokinetics of florfenicol in normal and <italic>Pasteurella</italic>-infected Muscovy ducks</article-title><source>Br Poultry Sci</source><year>1998</year><volume>39</volume><issue>4</issue><fpage>492</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1080/00071669888656</pub-id><pub-id pub-id-type="pmid">9800032</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinn</surname><given-names>B</given-names></name><name><surname>Hussain</surname><given-names>S</given-names></name><name><surname>Malik</surname><given-names>M</given-names></name><name><surname>Drlica</surname><given-names>K</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name></person-group><article-title>Daptomycin inoculum effects and mutant prevention concentration with <italic>Staphylococcus aureus</italic></article-title><source>J Antimicrob Chemother</source><year>2007</year><volume>60</volume><issue>6</issue><fpage>1380</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1093/jac/dkm375</pub-id><pub-id pub-id-type="pmid">17905797</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcusson</surname><given-names>LL</given-names></name><name><surname>Olofsson</surname><given-names>SK</given-names></name><name><surname>Lindgren</surname><given-names>PK</given-names></name><name><surname>Cars</surname><given-names>O</given-names></name><name><surname>Hughes</surname><given-names>D</given-names></name></person-group><article-title>Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of <italic>Escherichia coli</italic></article-title><source>J Antimicrob Chemother</source><year>2005</year><volume>55</volume><issue>6</issue><fpage>938</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1093/jac/dki136</pub-id><pub-id pub-id-type="pmid">15860549</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>J</given-names></name><name><surname>Cebrian</surname><given-names>L</given-names></name><name><surname>Lopez</surname><given-names>M</given-names></name><name><surname>Ruiz</surname><given-names>M</given-names></name><name><surname>Jimenez</surname><given-names>I</given-names></name><name><surname>Royo</surname><given-names>G</given-names></name></person-group><article-title>Mutant prevention concentration: comparison of fluoroquinolones and linezolid with <italic>Mycobacterium tuberculosis</italic></article-title><source>J Antimicrob Chemother</source><year>2004</year><volume>53</volume><issue>3</issue><fpage>441</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1093/jac/dkh119</pub-id><pub-id pub-id-type="pmid">14963069</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Credito</surname><given-names>K</given-names></name><name><surname>Kosowska-Shick</surname><given-names>K</given-names></name><name><surname>Appelbaum</surname><given-names>PC</given-names></name></person-group><article-title>Mutant prevention concentrations of four carbapenems against gram-negative rods</article-title><source>Antimicrob Agents Chemother</source><year>2010</year><volume>54</volume><issue>6</issue><fpage>2692</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1128/AAC.00033-10</pub-id><pub-id pub-id-type="pmid">20308376</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Credito</surname><given-names>K</given-names></name><name><surname>Kosowska-Shick</surname><given-names>K</given-names></name><name><surname>McGhee</surname><given-names>P</given-names></name><name><surname>Pankuch</surname><given-names>GA</given-names></name><name><surname>Appelbaum</surname><given-names>PC</given-names></name></person-group><article-title>Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci</article-title><source>Antimicrob Agents Chemother</source><year>2010</year><volume>54</volume><issue>2</issue><fpage>673</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1128/AAC.01353-09</pub-id><pub-id pub-id-type="pmid">20008781</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Yuanshu</surname><given-names>Z</given-names></name><name><surname>Yuhan</surname><given-names>Z</given-names></name><name><surname>Yingxia</surname><given-names>L</given-names></name></person-group><article-title>Mutant prevention concentrations of fluoroquinolones against <italic>Campylobacter jejuni</italic> isolated from chicken</article-title><source>Vet Microbiol</source><year>2010</year><volume>144</volume><issue>3</issue><fpage>409</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2010.02.020</pub-id><pub-id pub-id-type="pmid">20226601</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briales</surname><given-names>A</given-names></name><name><surname>Rodriguez-Martinez</surname><given-names>J</given-names></name><name><surname>Velasco</surname><given-names>C</given-names></name><name><surname>de Alba</surname><given-names>PD</given-names></name><name><surname>Dom&#x000ed;nguez-Herrera</surname><given-names>J</given-names></name><name><surname>Pach&#x000f3;n</surname><given-names>J</given-names></name><etal/></person-group><article-title>In vitro effect of <italic>qnrA1</italic>, <italic>qnrB1</italic>, and <italic>qnrS1</italic> genes on fluoroquinolone activity against isogenic <italic>Escherichia coli</italic> isolates with mutations in gyrA and parC</article-title><source>Antimicrob Agents Chemother</source><year>2011</year><volume>55</volume><issue>3</issue><fpage>1266</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1128/AAC.00927-10</pub-id><pub-id pub-id-type="pmid">21173174</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y-P</given-names></name><name><surname>Lee</surname><given-names>S-H</given-names></name><name><surname>Chou</surname><given-names>C-H</given-names></name><name><surname>Tsai</surname><given-names>H-J</given-names></name></person-group><article-title>Detection of florfenicol resistance genes in <italic>Riemerella anatipestifer</italic> isolated from ducks and geese</article-title><source>Vet Microbiol</source><year>2012</year><volume>154</volume><issue>3</issue><fpage>325</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2011.07.012</pub-id><pub-id pub-id-type="pmid">21820820</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zonca</surname><given-names>A</given-names></name><name><surname>Gallo</surname><given-names>M</given-names></name><name><surname>Locatelli</surname><given-names>C</given-names></name><name><surname>Carli</surname><given-names>S</given-names></name><name><surname>Moroni</surname><given-names>P</given-names></name><name><surname>Villa</surname><given-names>R</given-names></name><etal/></person-group><article-title>Cefquinome sulfate behavior after intramammary administration in healthy and infected cows</article-title><source>J Dairy Sci</source><year>2011</year><volume>94</volume><issue>7</issue><fpage>3455</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.3168/jds.2010-4109</pub-id><pub-id pub-id-type="pmid">21700031</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavaco</surname><given-names>L</given-names></name><name><surname>Abatih</surname><given-names>E</given-names></name><name><surname>Aarestrup</surname><given-names>FM</given-names></name><name><surname>Guardabassi</surname><given-names>L</given-names></name></person-group><article-title>Selection and persistence of CTX-M-producing <italic>Escherichia coli</italic> in the intestinal flora of pigs treated with amoxicillin, ceftiofur, or cefquinome</article-title><source>Antimicrob Agents Chemother</source><year>2008</year><volume>52</volume><issue>10</issue><fpage>3612</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1128/AAC.00354-08</pub-id><pub-id pub-id-type="pmid">18644956</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>C-F</given-names></name><name><surname>Lin</surname><given-names>W-H</given-names></name><name><surname>Yeh</surname><given-names>T-M</given-names></name><name><surname>Chiang</surname><given-names>T-S</given-names></name><name><surname>Chang</surname><given-names>Y-F</given-names></name></person-group><article-title>Antimicrobial susceptibility of <italic>Riemerella anatipestifer</italic> isolated from ducks and the efficacy of ceftiofur treatment</article-title><source>J Vet Diagn Invest</source><year>2003</year><volume>15</volume><issue>1</issue><fpage>26</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1177/104063870301500106</pub-id><pub-id pub-id-type="pmid">12580291</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olofsson</surname><given-names>SK</given-names></name><name><surname>Marcusson</surname><given-names>LL</given-names></name><name><surname>Lindgren</surname><given-names>PK</given-names></name><name><surname>Hughes</surname><given-names>D</given-names></name><name><surname>Cars</surname><given-names>O</given-names></name></person-group><article-title>Selection of ciprofloxacin resistance in <italic>Escherichia coli</italic> in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration</article-title><source>J Antimicrob Chemother</source><year>2006</year><volume>57</volume><issue>6</issue><fpage>1116</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/jac/dkl135</pub-id><pub-id pub-id-type="pmid">16624874</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Firsov</surname><given-names>AA</given-names></name><name><surname>Smirnova</surname><given-names>MV</given-names></name><name><surname>Lubenko</surname><given-names>IY</given-names></name><name><surname>Vostrov</surname><given-names>SN</given-names></name><name><surname>Portnoy</surname><given-names>YA</given-names></name><name><surname>Zinner</surname><given-names>SH</given-names></name></person-group><article-title>Testing the mutant selection window hypothesis with <italic>Staphylococcus aureus</italic> exposed to daptomycin and vancomycin in an in vitro dynamic model</article-title><source>J Antimicrob Chemother</source><year>2006</year><volume>58</volume><issue>6</issue><fpage>1185</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1093/jac/dkl387</pub-id><pub-id pub-id-type="pmid">17028094</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gebru</surname><given-names>E</given-names></name><name><surname>Damte</surname><given-names>D</given-names></name><name><surname>Choi</surname><given-names>M-J</given-names></name><name><surname>Lee</surname><given-names>S-J</given-names></name><name><surname>Kim</surname><given-names>Y-H</given-names></name><name><surname>Park</surname><given-names>SC</given-names></name></person-group><article-title>Mutant prevention concentration and phenotypic and molecular basis of fluoroquinolone resistance in clinical isolates and in vitro-selected mutants of <italic>Escherichia coli</italic> from dogs</article-title><source>Vet Microbiol</source><year>2012</year><volume>154</volume><issue>3</issue><fpage>384</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2011.07.033</pub-id><pub-id pub-id-type="pmid">21893387</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Gu</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><etal/></person-group><article-title>In vivo evaluation of mutant selection window of cefquinome against <italic>Escherichia coli</italic> in piglet tissue-cage model</article-title><source>BMC Vet Res</source><year>2014</year><volume>10</volume><issue>1</issue><fpage>297</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1186/s12917-014-0297-1</pub-id><pub-id pub-id-type="pmid">25511985</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Gu</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><etal/></person-group><article-title>Pharmacokinetics and ex vivo pharmacodynamics of cefquinome in porcine serum and tissue cage fluids</article-title><source>Vet J</source><year>2014</year><volume>199</volume><issue>3</issue><fpage>399</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1016/j.tvjl.2013.12.015</pub-id><pub-id pub-id-type="pmid">24423605</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Gu</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><etal/></person-group><article-title>Pharmacokinetics and ex-vivo pharmacodynamics of cefquinome against <italic>Klebsiella pneumonia</italic> in healthy dogs</article-title><source>J Vet Pharmacol Ther</source><year>2014</year><volume>37</volume><issue>4</issue><fpage>367</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1111/jvp.12100</pub-id><pub-id pub-id-type="pmid">24372291</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shan</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Ding</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Zeng</surname><given-names>Z</given-names></name></person-group><article-title>Pharmacokinetic/pharmacodynamic relationship of cefquinome against <italic>Pasteurella multocida</italic> in a tissue-cage model in yellow cattle</article-title><source>J Vet Pharmacol Ther</source><year>2014</year><volume>37</volume><issue>2</issue><fpage>178</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1111/jvp.12076</pub-id><pub-id pub-id-type="pmid">23980645</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shan</surname><given-names>Q</given-names></name><name><surname>Liang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zeng</surname><given-names>Z</given-names></name></person-group><article-title>In vivo activity of cefquinome against <italic>Escherichia coli</italic> in the thighs of neutropenic mice</article-title><source>Antimicrob Agents Chemother</source><year>2014</year><volume>58</volume><issue>10</issue><fpage>5943</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1128/AAC.03446-14</pub-id><pub-id pub-id-type="pmid">25070101</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Shan</surname><given-names>Q</given-names></name><name><surname>Ding</surname><given-names>H</given-names></name><name><surname>Liang</surname><given-names>C</given-names></name><name><surname>Zeng</surname><given-names>Z</given-names></name></person-group><article-title>Pharmacodynamics of cefquinome in a neutropenic mouse thigh model of <italic>Staphylococcus aureus</italic> infection</article-title><source>Antimicrob Agents Chemother</source><year>2014</year><volume>58</volume><issue>6</issue><fpage>3008</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1128/AAC.01666-13</pub-id><pub-id pub-id-type="pmid">24614373</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>R-J</given-names></name><name><surname>Huang</surname><given-names>T</given-names></name><name><surname>Qiao</surname><given-names>GG</given-names></name><etal/></person-group><article-title>In vitro dynamic pharmacokinetic/pharmacodynamic (PK/PD) modeling and PK/PD cutoff of cefquinome against <italic>Haemophilus parasuis</italic></article-title><source>BMC Vet Res</source><year>2015</year><volume>11</volume><issue>1</issue><fpage>33</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1186/s12917-015-0343-7</pub-id><pub-id pub-id-type="pmid">25889187</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Pharmacokinetics, bioavailability and PK/PD relationship of cefquinome for <italic>Escherichia coli</italic> in Beagle dogs</article-title><source>J Vet Pharmacol Ther</source><year>2015</year></element-citation></ref></ref-list></back></article>